TIDMOBD

RNS Number : 8094Q

Oxford BioDynamics PLC

15 September 2017

15 September 2017

Oxford BioDynamics Plc

Directorate update

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that further to the announcement on 30 June 2017, Paul Stockdale will join the Company as Chief Financial Officer and an Executive Director on the Board, with immediate effect.

For further details contact:

 
 Oxford BioDynamics Plc         +44 (0)1865 518910 
 Christian Hoyer Millar, 
  CEO 
 Paul Stockdale, CFO 
 
 Stifel Nicolaus Europe 
  Limited                       +44 (0)20 7710 7600 
 Nominated Advisor and 
  Broker 
 David Arch 
 Jonathan Senior 
 Peter Lees 
 Ben Maddison 
 
 Shore Capital                  +44 (0)20 7408 4090 
 Joint Broker 
 Bidhi Bhoma 
 Edward Mansfield 
 
 FTI Consulting                 +44 (0)20 3727 1000 
 Financial Public Relations 
  Advisor 
 Julia Phillips 
 Brett Pollard 
 Natalie Garland-Collins

Appendix - Schedule Two Information

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
  Current directorships   Past Directorships 
  None                    PL & JE Services 
                           Limited

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue--generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABUGDCBXBBGRS

(END) Dow Jones Newswires

September 15, 2017 02:00 ET (06:00 GMT)

Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Oxford Biodynamics Charts.
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Oxford Biodynamics Charts.